Strong MS Drugs Cut Relapses but Not Silent Progression

Credibility

Interest

Key Takeaway

High‑strength MS drugs better control relapses and MRI activity, but both high- and moderate-strength drugs show similar limits at preventing disability that happens without relapses or new MRI lesions (PIRMA).

What They Found

Researchers looked at over 10,000 people with relapsing MS treated in France for about 3.7 years on average. Patients who started on high-efficacy therapies (HET) had slightly earlier first PIRMA events than those on moderate-efficacy therapies (MET), but the difference was very small. HET tended to delay overall confirmed disability worsening more than MET, probably because HET better prevented relapses and new MRI lesions that can cause stepping-up disability. The study found that attacks (relapses) and new MRI changes were better controlled by HET, but the part of disability that develops without relapses or MRI changes (PIRMA) seemed to occur at similar rates with either type of treatment. People who were older, already had higher disability scores, or had spinal cord lesions at the start were more likely to experience PIRMA.

Who Should Care and Why

People with relapsing MS should care because this study shows that strong treatments help prevent relapses and new MRI damage, which are common causes of short-term disability. Caregivers and family members can use this to understand why a doctor might recommend stronger therapy to reduce flare-ups, like choosing a stronger umbrella in a heavy storm to avoid getting soaked. Patients who already have more disability, are older, or have spinal cord lesions should pay special attention because they are at higher risk for PIRMA even when flares and MRI activity are controlled. Clinicians and MS nurses can use this information to explain that some disability can progress quietly (without clear relapses or MRI changes), so close monitoring and tailored care remain important. The result may affect daily care plans by encouraging more regular check-ins, symptom tracking, and discussions about goals of therapy beyond just preventing relapses.

Important Considerations

This was an observational real-world study, not a randomized trial, so differences between groups could be influenced by factors not fully measured, like why a doctor chose a particular drug. Follow-up averaged under four years, which may be too short to see long-term differences in slow disability that develops without relapses or MRI changes. The small statistical differences reported may not always mean noticeable changes for an individual patient, so decisions about treatment should still be personalized with your care team.

Categories:

MS Progression Treatment Updates Clinical Trials

Article Topics:

disabilityhigh-efficacy therapymultiple sclerosisprogression independent of relapse and MRI activitytreatment

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Brain : a journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News